Editas Medication (NASDAQ:EDIT – Get Ranking) had its value goal lowered by Chardan Capital from $75.00 to $60.00 in a analysis report despatched to traders on Friday, The Fly stories. Chardan Capital presently has a purchase ranking on the inventory.
EDIT has been the subject of a number of different stories. SVB Leerink dropped their value goal on Editas Medication from $41.00 to $27.00 and set a market carry out ranking on the inventory in a analysis word on Friday. Evercore ISI reduce Editas Medication to a maintain ranking and set a $15.00 goal value on the inventory. in a analysis word on Friday, February eleventh. Zacks Funding Analysis upgraded Editas Medication from a maintain ranking to a purchase ranking and set a $20.00 goal value on the inventory in a analysis word on Thursday, February third. Morgan Stanley lowered their goal value on Editas Medication from $37.00 to $24.00 and set an underweight ranking on the inventory in a analysis word on Thursday, January sixth. Lastly, Oppenheimer lowered their goal value on Editas Medication from $80.00 to $55.00 and set an outperform ranking on the inventory in a analysis word on Friday. Two analysis analysts have rated the inventory with a promote ranking, 5 have assigned a maintain ranking and 6 have issued a purchase ranking to the corporate’s inventory. Primarily based on information from MarketBeat.com, the inventory presently has a consensus ranking of Maintain and a consensus goal value of $38.58.
Shares of NASDAQ:EDIT opened at $17.12 on Friday. The inventory’s fifty day easy shifting common is $20.98 and its two-hundred day easy shifting common is $36.67. Editas Medication has a 1-year low of $13.25 and a 1-year excessive of $73.03. The inventory has a market cap of $1.17 billion, a PE ratio of -6.01 and a beta of two.03.
Editas Medication (NASDAQ:EDIT – Get Ranking) final issued its quarterly earnings information on Thursday, February twenty fourth. The corporate reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.28. Editas Medication had a damaging return on fairness of 31.42% and a damaging web margin of 753.61%. The enterprise had income of $12.50 million for the quarter, in comparison with analysts’ expectations of $4.70 million. Throughout the identical interval final yr, the enterprise earned ($1.00) EPS. The enterprise’s income was up 9.6% on a year-over-year foundation. Equities analysis analysts forecast that Editas Medication will put up -3.42 earnings per share for the present yr.
In associated information, CFO Michelle Robertson offered 1,744 shares of Editas Medication inventory in a transaction dated Tuesday, January eleventh. The inventory was offered at a median value of $25.70, for a complete worth of $44,820.80. The sale was disclosed in a doc filed with the Securities & Change Fee, which is accessible by the SEC web site. Firm insiders personal 0.94% of the corporate’s inventory.
Various hedge funds have just lately purchased and offered shares of the enterprise. Wedbush Securities Inc. grew its holdings in Editas Medication by 5.6% in the course of the third quarter. Wedbush Securities Inc. now owns 5,615 shares of the corporate’s inventory valued at $231,000 after shopping for an extra 300 shares within the final quarter. Macquarie Group Ltd. grew its holdings in Editas Medication by 19.7% in the course of the 2nd quarter. Macquarie Group Ltd. now owns 1,957 shares of the corporate’s inventory valued at $111,000 after shopping for an extra 322 shares within the final quarter. DekaBank Deutsche Girozentrale grew its holdings in Editas Medication by 3.0% in the course of the 4th quarter. DekaBank Deutsche Girozentrale now owns 20,400 shares of the corporate’s inventory valued at $545,000 after shopping for an extra 600 shares within the final quarter. Cetera Advisor Networks LLC grew its holdings in Editas Medication by 8.4% in the course of the third quarter. Cetera Advisor Networks LLC now owns 8,667 shares of the corporate’s inventory valued at $356,000 after shopping for an extra 671 shares within the final quarter. Lastly, CKW Monetary Group bought a brand new place in Editas Medication in the course of the third quarter valued at about $28,000. 67.71% of the inventory is owned by institutional traders and hedge funds.
About Editas Medication (Get Ranking)
Editas Medication, Inc engages within the improvement and commercialization of genome modifying expertise. Its expertise consists of clustered, often interspaced quick palindromic repeats (CRISPR), and CRISPR related protein 9 (Cas9). The corporate was based by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.
Need Extra Nice Investing Concepts?
Obtain Information & Scores for Editas Medication Each day – Enter your e-mail tackle under to obtain a concise day by day abstract of the most recent information and analysts’ rankings for Editas Medication and associated corporations with MarketBeat.com’s FREE day by day e-mail e-newsletter.